---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-24-000034"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:11:44.007278+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Humacyte BLA for HAV gets Priority Review; PDUFA Aug 10, 2024; Q4 net loss $25.1M

## Summary
- FDA accepted BLA for HAV with Priority Review in vascular trauma; PDUFA date August 10, 2024.
- Raised ~$43.1M net from public offering in March 2024; additional $20M draw from Oberland.
- Cash and equivalents $80.4M at Dec 31, 2023; net cash used $69.0M in 2023.
- No revenue in Q4 2023; R&D expenses $20.2M (up from $15.0M), net loss $25.1M.
- Full year 2023 net loss $110.8M vs $12.0M in 2022 due to non-cash remeasurement and higher expenses.

## SEC filing metadata
- accession: 0001818382-24-000034
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000034/0001818382-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000034/huma-20240322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-24-000034
- JSON: https://secwatch.observer/filing/0001818382-24-000034.json
- Plain text: https://secwatch.observer/filing/0001818382-24-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.